Read original blog entry
Johnson & Johnson (JNJ) is one of the world's largest providers of healthcare products in the consumer, pharmaceutical and medical devices market. It has over 200 operating companies around the world and sells its products in more than 175 countries. J&J has an enormously diverse revenue stream consisting of market leading products in all three of its business segments.
Due to a number of products expected to experience declining sales, revenue growth in the next few years will likely slow relative to 2007. Incremental earnings growth will come in the form of improving margins and share buybacks. J&J's consistency, product diversity and financial stability make it a very attractive holding in this turbulent market.
We rate the stock a Buy based on the stock s attractive valuation and strong company fundamentals. Our price target is $72.
Read the full analyst report on JNJ.
Get real-time market insights and profitable stock recommendations from the team of analysts at Zacks Equity Research. See all todays Analyst Blog entries on Zacks.com.